United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
BASEL, Switzerland and CAMBRIDGE, Mass., April 27, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel in Boston, MA.
Event: 42nd Annual Deutsche Bank Health Care Conference
Date: Wednesday, May 3rd
Time: 4:10 PM EDT
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
